FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087202011> ?p ?o ?g. }

• W2087202011 endingPage "488" @default.
• W2087202011 startingPage "482" @default.
• W2087202011 abstract "Background Trastuzumab has been approved for use in combination with fluoropyrimidine plus cisplatin for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC). Although capecitabine plus oxaliplatin (XELOX) is a standard first-line regimen for AGC, combination trastuzumab plus XELOX has not been studied. Methods Patients with metastatic or unresectable HER2-positive AGC were diagnosed by either HER2 immunohistochemistry (IHC) 3+ or IHC 2+/fluorescence in-situ hybridisation (FISH)+ received intravenous trastuzumab (8 mg/kg for first cycle and 6 mg/kg for subsequent cycles on day 1) plus oral capecitabine (1000 mg/m2 twice daily on days 1–14) and intravenous oxaliplatin (130 mg/m2 on day 1), every 3 weeks. The primary end-point was the objective response rate, and secondary end-points included progression-free survival (PFS), overall survival (OS) and toxicity profiles. Results Fifty-five HER2-positive AGC patients were enrolled between August 2011 and February 2013. The median age was 57 years (range = 29–74). The confirmed objective response rate was 67% (95% confidence interval (CI) = 54–80%). After a median follow-up period of 13.8 months (range = 6.1–23.9), the median PFS and OS were 9.8 months (95% CI = 7.0–12.6) and 21.0 months (95% CI = 6.4–35.7), respectively. Frequently encountered grade 3–4 toxicities included neutropenia (18%), anaemia (11%), and peripheral neuropathy (11%). There was a treatment-related death caused by severe diarrhoea and complicated sepsis. Conclusion Combination of trastuzumab and XELOX is well tolerated and highly effective in patients with HER2-positive AGC." @default.
• W2087202011 created "2016-06-24" @default.
• W2087202011 creator A5001179320 @default.
• W2087202011 creator A5006577120 @default.
• W2087202011 creator A5008267854 @default.
• W2087202011 creator A5010177061 @default.
• W2087202011 creator A5017172069 @default.
• W2087202011 creator A5038041478 @default.
• W2087202011 creator A5048145361 @default.
• W2087202011 creator A5062088034 @default.
• W2087202011 creator A5062251564 @default.
• W2087202011 creator A5062301570 @default.
• W2087202011 creator A5090754319 @default.
• W2087202011 creator A5091587460 @default.
• W2087202011 date "2015-03-01" @default.
• W2087202011 modified "2023-09-25" @default.
• W2087202011 title "Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer" @default.
• W2087202011 cites W1987009448 @default.
• W2087202011 cites W2007093497 @default.
• W2087202011 cites W2019607817 @default.
• W2087202011 cites W2059755429 @default.
• W2087202011 cites W2100439220 @default.
• W2087202011 cites W2108661938 @default.
• W2087202011 cites W2110577005 @default.
• W2087202011 cites W2127773543 @default.
• W2087202011 cites W2128328462 @default.
• W2087202011 cites W2140663796 @default.
• W2087202011 cites W2142416576 @default.
• W2087202011 cites W2143809951 @default.
• W2087202011 cites W2155588015 @default.
• W2087202011 cites W2169560977 @default.
• W2087202011 cites W2915373011 @default.
• W2087202011 cites W4362207802 @default.
• W2087202011 doi "https://doi.org/10.1016/j.ejca.2014.12.015" @default.
• W2087202011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25661103" @default.
• W2087202011 hasPublicationYear "2015" @default.
• W2087202011 type Work @default.
• W2087202011 sameAs 2087202011 @default.
• W2087202011 citedByCount "97" @default.
• W2087202011 countsByYear W20872020112015 @default.
• W2087202011 countsByYear W20872020112016 @default.
• W2087202011 countsByYear W20872020112017 @default.
• W2087202011 countsByYear W20872020112018 @default.
• W2087202011 countsByYear W20872020112019 @default.
• W2087202011 countsByYear W20872020112020 @default.
• W2087202011 countsByYear W20872020112021 @default.
• W2087202011 countsByYear W20872020112022 @default.
• W2087202011 countsByYear W20872020112023 @default.
• W2087202011 crossrefType "journal-article" @default.
• W2087202011 hasAuthorship W2087202011A5001179320 @default.
• W2087202011 hasAuthorship W2087202011A5006577120 @default.
• W2087202011 hasAuthorship W2087202011A5008267854 @default.
• W2087202011 hasAuthorship W2087202011A5010177061 @default.
• W2087202011 hasAuthorship W2087202011A5017172069 @default.
• W2087202011 hasAuthorship W2087202011A5038041478 @default.
• W2087202011 hasAuthorship W2087202011A5048145361 @default.
• W2087202011 hasAuthorship W2087202011A5062088034 @default.
• W2087202011 hasAuthorship W2087202011A5062251564 @default.
• W2087202011 hasAuthorship W2087202011A5062301570 @default.
• W2087202011 hasAuthorship W2087202011A5090754319 @default.
• W2087202011 hasAuthorship W2087202011A5091587460 @default.
• W2087202011 hasConcept C121608353 @default.
• W2087202011 hasConcept C126322002 @default.
• W2087202011 hasConcept C141071460 @default.
• W2087202011 hasConcept C143998085 @default.
• W2087202011 hasConcept C203092338 @default.
• W2087202011 hasConcept C2776694085 @default.
• W2087202011 hasConcept C2777063308 @default.
• W2087202011 hasConcept C2777909004 @default.
• W2087202011 hasConcept C2779786085 @default.
• W2087202011 hasConcept C2780962732 @default.
• W2087202011 hasConcept C2781413609 @default.
• W2087202011 hasConcept C526805850 @default.
• W2087202011 hasConcept C530470458 @default.
• W2087202011 hasConcept C535046627 @default.
• W2087202011 hasConcept C71924100 @default.
• W2087202011 hasConcept C90924648 @default.
• W2087202011 hasConceptScore W2087202011C121608353 @default.
• W2087202011 hasConceptScore W2087202011C126322002 @default.
• W2087202011 hasConceptScore W2087202011C141071460 @default.
• W2087202011 hasConceptScore W2087202011C143998085 @default.
• W2087202011 hasConceptScore W2087202011C203092338 @default.
• W2087202011 hasConceptScore W2087202011C2776694085 @default.
• W2087202011 hasConceptScore W2087202011C2777063308 @default.
• W2087202011 hasConceptScore W2087202011C2777909004 @default.
• W2087202011 hasConceptScore W2087202011C2779786085 @default.
• W2087202011 hasConceptScore W2087202011C2780962732 @default.
• W2087202011 hasConceptScore W2087202011C2781413609 @default.
• W2087202011 hasConceptScore W2087202011C526805850 @default.
• W2087202011 hasConceptScore W2087202011C530470458 @default.
• W2087202011 hasConceptScore W2087202011C535046627 @default.
• W2087202011 hasConceptScore W2087202011C71924100 @default.
• W2087202011 hasConceptScore W2087202011C90924648 @default.
• W2087202011 hasFunder F4320307779 @default.
• W2087202011 hasFunder F4320307781 @default.
• W2087202011 hasIssue "4" @default.
• W2087202011 hasLocation W20872020111 @default.
• W2087202011 hasOpenAccess W2087202011 @default.

• next